active surveillance for Prostate Cancer

active surveillance for prostate cancer is a structured plan that postpones immediate treatment while a physician closely monitors the cancer. It’s most often considered for carefully selected men with localized, low-risk prostate cancer that is expected to grow slowly. Instead of beginning brachytherapy, external beam radiation, hormone therapy, or surgery right away, the patient follows a schedule of tests and appointments. This approach may delay or avoid the side effects of prostate cancer treatment while keeping treatment options available if new findings show a meaningful change.

active surveillance is an accepted medical approach, but it is not appropriate for every patient. The decision should be based on the diagnosis, overall health, personal priorities, and ability to complete regular prostate cancer follow-up. Talk with your physician about the benefits and limitations in the context of your health situation.

Choosing surveillance does not mean ignoring the diagnosis. It means following a medical plan designed to detect changes while there is still an opportunity to discuss treatment. Patients should understand the schedule, the purpose of each test, and the findings that may lead to another evaluation.

Who May Be a Candidate for active surveillance?

Doctors commonly consider active surveillance for men with localized prostate cancer in a low-risk category. They may review PSA results, biopsy findings, Gleason score, grade Group, the amount of prostate cancer found in biopsy samples, age, other health conditions, and the patient’s preferences.

Candidates should also be:

• Able to live with a cancer diagnosis without anxiety affecting their quality of life
• Willing and able to attend scheduled exams, PSA tests, imaging, and biopsies
• Interested in delaying or avoiding potential treatment effects when the medical findings support surveillance

Concern about treatment effects may influence the decision, but it should not be the only factor. A physician can explain how the cancer’s risk category and the demands of prostate cancer monitoring apply to the individual patient.

active surveillance Guidelines

Eligibility standards can differ among medical practices and surveillance programs. Some clinical features a physician may consider include:

• Gleason score 3+3=6 or 3+4=7 (if very low percentage of core)
• PSA less than 10
• No more than 2 positive cores or cancer involving no more than 50% of any core
• A small tumor expected to grow slowly
• Cancer confined to the prostate

These points should be reviewed as part of the full medical picture rather than used as a universal checklist. The physician may weigh the grade Group, PSA pattern, biopsy details, imaging, health history, and other information before recommending active surveillance for prostate cancer.

What active surveillance for Prostate Cancer Involves

The care team begins with information already gathered during diagnosis, including PSA results and the pathology report from the prostate biopsy. Those findings provide a baseline for comparing later results. The physician then recommends a follow-up plan based on the patient’s age, health, risk category, and medical findings.

Follow-up may include office visits, PSA testing, digital rectal examinations, imaging, and repeat biopsies. These evaluations help the physician look for signs that the prostate cancer may be changing. One PSA value or test result may not provide the full answer, so the care team may review patterns and findings together.

Serial monitoring may include:

• PSA testing every 3-6 months
• Digital Rectal Exam at least once a year
• Prostate biopsy every 1-2 years

Monitoring schedules can vary, and the physician may recommend a different interval or additional testing. Patients should attend scheduled appointments, complete the recommended tests, and ask what changes or symptoms should be reported between visits.

At follow-up visits, patients can ask how the latest PSA result compares with earlier results and what a biopsy or scan shows. They can also confirm the next appointment, which tests are planned, and who to contact with questions. Keeping copies of results can make the plan easier to follow.

Benefits and Limitations of active surveillance

For an appropriately selected patient, active surveillance can delay prostate cancer treatment and its potential urinary, bowel, sexual, or hormonal effects. It also gives the care team a way to watch the cancer and discuss treatment if the findings change.

This approach also requires a long-term commitment to appointments and repeated testing. A biopsy or another test may be uncomfortable, and living with diagnosed prostate cancer without starting treatment can cause anxiety. Initial testing may also miss information that appears in a later biopsy or scan.

Patients should discuss their comfort with surveillance, concerns about testing, and priorities with their physician. A partner, caregiver, or family member can join appointments and help keep track of questions and follow-up instructions.

When Treatment May Be Considered

active surveillance keeps the option of future treatment open. The care team may recommend further evaluation if biopsy findings, grade Group, imaging, PSA results, symptoms, or other clinical information change. Decisions are usually based on the overall pattern rather than one result by itself.

A patient’s health, priorities, or comfort with continued surveillance may change as well. If prostate cancer treatment becomes appropriate, the physician should explain the available treatment options and how they relate to the patient’s current findings.

Beginning treatment later does not mean the surveillance plan failed. active surveillance is designed to monitor selected cancers and identify a point when the potential benefits of treatment may outweigh the reasons for waiting.

active surveillance vs. Watchful Waiting

active surveillance and watchful waiting both delay immediate prostate cancer treatment, but they have different goals. active surveillance uses planned tests and appointments to look for changes that could lead to treatment intended to control or remove the cancer.

Watchful waiting generally places more emphasis on symptoms and comfort. Treatment may be used to manage symptoms if they develop. A physician can explain which approach may fit the patient’s cancer, overall health, life expectancy, and goals.

Frequently Asked Questions About active surveillance

How Long Can You Stay on active surveillance?

There is no universal time limit. Some patients may remain on active surveillance for years as long as their medical findings and personal circumstances continue to support the plan. The physician will review test results and determine if continued surveillance remains appropriate.

Is active surveillance Safe for Prostate Cancer?

active surveillance is an accepted approach for appropriately selected men with low-risk prostate cancer. Its safety depends on careful patient selection and regular monitoring. Skipping appointments or recommended tests can make it harder for the care team to identify a change that may need attention.

Can You Begin Treatment Later?

Yes. Treatment can be discussed if the cancer shows signs of change or if the patient’s health, priorities, or comfort with surveillance changes. The medical team can explain which treatment options may be appropriate at that point.

Resources

active surveillance Patients International: https://aspatients.org/

The Active Surveillor: https://howardwolinsky.substack.com/

Find Support Through PCFC and Wellness House

PCFC can serve as a local starting point for patients and families dealing with prostate cancer. Its free prostate cancer support group meets at Wellness House in Hinsdale on the first Wednesday of each month, with no meetings in January or July. Patients, caregivers, and family members are welcome.

Wellness House also offers prostate cancer programs related to emotional health, exercise, nutrition, and caregiver support. The foundation supports this work and fully sponsors the Wellness House staff member who leads prostate cancer outreach. Learn more about the available resources or attend a meeting to connect with people who understand the experience.